PROCEPT BioRobotics (PRCT) Net Cash Flow (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported Net Cash Flow for 7 consecutive years, with -$17.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 31.49% year-over-year to -$17.7 million in Q2 2026; TTM through Jun 2026 was -$74.7 million, a 184.26% decrease from a year earlier, with the FY2025 full-year figure at -$47.1 million, down 161.63% from the prior year.
• Net Cash Flow was -$17.7 million for Q2 2026 at PROCEPT BioRobotics, up from -$40.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $137.4 million in Q3 2023 and troughed at -$40.9 million in Q1 2023.
• A 5-year average of -$4.1 million and a median of -$17.4 million in 2024 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 767.36% in 2023, down 140.58% in 2023.
• Over 5 years, Net Cash Flow stood at -$27.4 million in 2022, then retreated by 12.0% to -$30.6 million in 2023, then jumped by 546.98% to $137.0 million in 2024, then plunged by 105.65% to -$7.7 million in 2025, then tumbled by 128.87% to -$17.7 million in 2026.
• The last three Net Cash Flow figures came in at -$17.7 million (Q2 2026), -$40.8 million (Q1 2026), and -$7.7 million (Q4 2025), per Business Quant data.